{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:57:09Z","timestamp":1793858229006,"version":"4.6.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s10637-015-0212-z","type":"journal-article","created":{"date-parts":[[2015,1,30]],"date-time":"2015-01-30T19:43:20Z","timestamp":1422647000000},"page":"720-728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":120,"title":["Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer"],"prefix":"10.1007","volume":"33","author":[{"given":"Khanh","family":"Do","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Speranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonny","family":"Khin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Kinders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Datiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Eugeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Austin","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Doroshow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaani","family":"Kummar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,1]]},"reference":[{"issue":"5","key":"212_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/gcc.20854","volume":"50","author":"CP Vaughn","year":"2011","unstructured":"Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS (2011) Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 50(5):307\u2013312. doi:10.1002\/gcc.20854","journal-title":"Genes Chromosomes Cancer"},{"issue":"15","key":"212_CR2","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29(15):2011\u20132019. doi:10.1200\/JCO.2010.33.5091","journal-title":"J Clin Oncol"},{"issue":"1","key":"212_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/carcin\/23.1.201","volume":"23","author":"HK Roy","year":"2002","unstructured":"Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT, Smyrk TC (2002) AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23(1):201\u2013205","journal-title":"Carcinogenesis"},{"issue":"13","key":"212_CR4","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-11-3747","volume":"72","author":"AB Turke","year":"2012","unstructured":"Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA (2012) MEK inhibition leads to PI3K\/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 72(13):3228\u20133237. doi:10.1158\/0008-5472.CAN-11-3747","journal-title":"Cancer Res"},{"issue":"17","key":"212_CR5","doi-asserted-by":"publisher","first-page":"6804","DOI":"10.1158\/0008-5472.CAN-10-0409","volume":"70","author":"E Halilovic","year":"2010","unstructured":"Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N (2010) PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK\/ERK and mutant KRAS signaling. Cancer Res 70(17):6804\u20136814. doi:10.1158\/0008-5472.CAN-10-0409","journal-title":"Cancer Res"},{"issue":"suppl","key":"212_CR6","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1200\/jco.2011.29.15_suppl.3037","volume":"29","author":"A Biondo","year":"2011","unstructured":"Biondo A, Yap TA, Yan L, Patnaik A, Fearen I, Baird RD, Papadopoulos KP, Delgado LM, Taylor A, Lupinacci L, Blackman SC, Decordova S, Tall M, Heaton S, Garrett MD, Sullivan D, De Bono JS, Tolcher AW (2011) Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors. J Clin Oncol 29(suppl):3037, abstract","journal-title":"J Clin Oncol"},{"issue":"35","key":"212_CR7","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1200\/JCO.2011.35.5263","volume":"29","author":"TA Yap","year":"2011","unstructured":"Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29(35):4688\u20134695. doi:10.1200\/JCO.2011.35.5263","journal-title":"J Clin Oncol"},{"issue":"8","key":"212_CR8","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1158\/1535-7163.MCT-07-0231","volume":"6","author":"BR Davies","year":"2007","unstructured":"Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase 1\/2 kinases: mechanism of action in vivo, pharmacokinetic\/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6(8):2209\u20132219. doi:10.1158\/1535-7163.MCT-07-0231","journal-title":"Mol Cancer Ther"},{"key":"212_CR9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1901","author":"AW Tolcher","year":"2014","unstructured":"Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS (2014) Anti-tumour activity in RAS-driven tumours by blocking AKT and MEK. Clin Cancer Res. doi:10.1158\/1078-0432.CCR-14-1901","journal-title":"Clin Cancer Res"},{"issue":"7","key":"212_CR10","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","volume":"9","author":"H Hirai","year":"2010","unstructured":"Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9(7):1956\u20131967. doi:10.1158\/1535-7163.MCT-09-1012","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"212_CR11","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/sim.3840","volume":"29","author":"LV Rubinstein","year":"2010","unstructured":"Rubinstein LV, Steinberg SM, Kummar S, Kinders R, Parchment RE, Murgo AJ, Tomaszewski JE, Doroshow JH (2010) The statistics of phase 0 trials. Stat Med 29(10):1072\u20131076. doi:10.1002\/sim.3840","journal-title":"Stat Med"},{"issue":"2","key":"212_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. doi:10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"13","key":"212_CR13","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","volume":"26","author":"AA Adjei","year":"2008","unstructured":"Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26(13):2139\u20132146. doi:10.1200\/JCO.2007.14.4956","journal-title":"J Clin Oncol"},{"issue":"5","key":"212_CR14","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1158\/1078-0432.CCR-09-2483","volume":"16","author":"U Banerji","year":"2010","unstructured":"Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM (2010) The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1\/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 16(5):1613\u20131623. doi:10.1158\/1078-0432.CCR-09-2483","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"212_CR15","doi-asserted-by":"crossref","first-page":"e13599","DOI":"10.1200\/jco.2012.30.15_suppl.e13599","volume":"30","author":"KH Khan","year":"2012","unstructured":"Khan KH, Yan L, Mezynski J, Patnaik A, Moreno V, Papadopoulos KP, Garrett CR, Ong M, Shannon KA, Morosky A, Rubin EH, Tetteh E, Skolnik J, Smith IC, Smith PD, De Bono JS, Tolcher AW (2012) A phase I dose escalation study of oral MK-2206 (allosteric Akt inhibitor) with oral selumetinib (AZD6244; ARRY-142866) (MEK 1\/2 inhibitor) in patients with advanced or metastatic solid tumors. J Clin Oncol 30(suppl):e13599, abstract","journal-title":"J Clin Oncol"},{"issue":"13","key":"212_CR16","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.ejca.2011.03.029","volume":"47","author":"T Watanabe","year":"2011","unstructured":"Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Ikeuchi H, Eshima K (2011) Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. Eur J Cancer 47(13):1946\u20131954. doi:10.1016\/j.ejca.2011.03.029","journal-title":"Eur J Cancer"},{"issue":"12","key":"212_CR17","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2174\/138945012803530062","volume":"13","author":"JE Ang","year":"2012","unstructured":"Ang JE, Kaye S, Banerji U (2012) Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials. Curr Drug Targets 13(12):1525\u20131534","journal-title":"Curr Drug Targets"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0212-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-015-0212-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0212-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0212-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T23:40:19Z","timestamp":1678491619000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-015-0212-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,1]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["212"],"URL":"https:\/\/doi.org\/10.1007\/s10637-015-0212-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,1]]},"assertion":[{"value":"12 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}